{"id":45335,"date":"2025-10-30T23:01:16","date_gmt":"2025-10-30T15:01:16","guid":{"rendered":"https:\/\/flcube.com\/?p=45335"},"modified":"2025-10-30T23:01:17","modified_gmt":"2025-10-30T15:01:17","slug":"modex-therapeutics-locks-1-b-collaboration-with-regeneron-on-multispecific-antibody-technology","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45335","title":{"rendered":"ModeX Therapeutics Locks $1\u202fB+ Collaboration With Regeneron on Multispecific Antibody Technology"},"content":{"rendered":"\n<p><strong>ModeX Therapeutics Inc.<\/strong>, an OPKO Health company (<a href=\"https:\/\/www.google.com\/finance\/quote\/OPK:NASDAQ\">NASDAQ: OPK<\/a>) announced a milestone license and collaboration agreement with <strong>Regeneron Pharmaceuticals Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/REGN:NASDAQ\">NASDAQ: REGN<\/a>)<\/strong> to develop multispecific antibodies across therapeutic areas of shared interest. The partnership will leverage ModeX\u2019s proprietary MSTAR (Multispecific Targeting for Antibody Recombinant) platform together with Regeneron\u2019s exclusive binding libraries, creating single\u2011molecule therapies that can target two or more distinct biological pathways simultaneously.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-deal-highlights\">Key Deal Highlights<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Upfront cash:<\/strong> ModeX receives <strong>US\u202f$7\u202fmillion<\/strong> to kick\u2011start the collaboration.<\/li>\n\n\n\n<li><strong>Future upside:<\/strong> Potential product\u2011selection, clinical, regulatory, and commercial milestone payments could exceed <strong>US\u202f$200\u202fmillion per molecule<\/strong>.<\/li>\n\n\n\n<li><strong>Total value:<\/strong> If multiple candidates reach the clinic, the partnership could hit <strong>over US\u202f$1\u202fbillion<\/strong>.<\/li>\n\n\n\n<li><strong>Royalties:<\/strong> Tiered global net\u2011sales royalties capped at low double\u2011digits for the highest tier.<\/li>\n\n\n\n<li><strong>Regeneron\u2019s role:<\/strong> Regeneron will finance and oversee pre\u2011clinical, clinical, and commercialization efforts for any product it chooses to advance.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-why-multispecific-antibodies-matter\">Why Multispecific Antibodies Matter<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Simplified dosing:<\/strong> One drug can substitute several monotherapies, potentially improving patient adherence.<\/li>\n\n\n\n<li><strong>Enhanced efficacy:<\/strong> Simultaneous blockade of complementary pathways may produce greater tumor control in oncology or superior disease modulation in immune\u2011mediated indications.<\/li>\n\n\n\n<li><strong>Reduced resistance:<\/strong> Co\u2011targeting key nodes within a disease network limits the emergence of escape mechanisms commonly seen with monospecific therapeutics.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-fit-for-modex\">Strategic Fit for ModeX<\/h2>\n\n\n\n<p>ModeX remains a <strong>subsidiary of OPKO Health<\/strong>, and the MSTAR technology positions it as a specialist in next\u2011generation antibody design. By partnering with Regeron\u2014a leader in antibody engineering\u2014the company can bring its platform to scale and benefit from Gen\u20115\u2011stage expertise in late\u2011stage development and global marketing.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-implications-for-the-biopharma-landscape\">Implications for the Biopharma Landscape<\/h2>\n\n\n\n<p>The alliance underscores a broader industry trend toward multispecific modalities, especially as competitors such as <strong>Amgen<\/strong>, <strong>Genentech<\/strong>, and <strong>Johnson\u202f&amp;\u202fJohnson<\/strong> deepen their own pipelines. If successful, ModeX and Regeneron could capture a sizable slice of the anti\u2011cancer and anti\u2011inflammatory antibody market, both of which are projected to exceed <strong>US\u202f$150\u202fbillion<\/strong> in global sales over the next decade.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-investor-viewpoint\">Investor Viewpoint<\/h3>\n\n\n\n<p>For investors, the deal offers a clear, tiered economic structure\u2014upfront funds, milestone payoffs, and royalty upside\u2014while reducing financial risk on the pre\u2011clinical side by handing those obligations to Regeneron. Market analysts will keenly watch the first clinical milestones and any subsequent product selection decisions, as these will determine the collaborative portfolio\u2019s scale and the ultimate return on the envisaged <strong>$1\u202fbillion<\/strong> opportunity.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK) announced a milestone license and collaboration&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45340,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2799,28,4418,1166,4419,1426],"class_list":["post-45335","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-modex-therapeutics","tag-multi-specific-antibodies","tag-nasdaq-opk","tag-nasdaq-regn","tag-opko-health","tag-regeneron-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>ModeX Therapeutics Locks $1\u202fB+ Collaboration With Regeneron on Multispecific Antibody Technology - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK) announced a milestone license and collaboration agreement with Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) to develop multispecific antibodies across therapeutic areas of shared interest. The partnership will leverage ModeX\u2019s proprietary MSTAR (Multispecific Targeting for Antibody Recombinant) platform together with Regeneron\u2019s exclusive binding libraries, creating single\u2011molecule therapies that can target two or more distinct biological pathways simultaneously.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45335\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ModeX Therapeutics Locks $1\u202fB+ Collaboration With Regeneron on Multispecific Antibody Technology\" \/>\n<meta property=\"og:description\" content=\"ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK) announced a milestone license and collaboration agreement with Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) to develop multispecific antibodies across therapeutic areas of shared interest. The partnership will leverage ModeX\u2019s proprietary MSTAR (Multispecific Targeting for Antibody Recombinant) platform together with Regeneron\u2019s exclusive binding libraries, creating single\u2011molecule therapies that can target two or more distinct biological pathways simultaneously.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45335\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-30T15:01:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-30T15:01:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3006-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45335#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45335\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"ModeX Therapeutics Locks $1\u202fB+ Collaboration With Regeneron on Multispecific Antibody Technology\",\"datePublished\":\"2025-10-30T15:01:16+00:00\",\"dateModified\":\"2025-10-30T15:01:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45335\"},\"wordCount\":410,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45335#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3006-1.webp\",\"keywords\":[\"ModeX Therapeutics\",\"Multi-specific antibodies\",\"NASDAQ: OPK\",\"NASDAQ: REGN\",\"OPKO Health\",\"Regeneron Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45335#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45335\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45335\",\"name\":\"ModeX Therapeutics Locks $1\u202fB+ Collaboration With Regeneron on Multispecific Antibody Technology - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45335#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45335#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3006-1.webp\",\"datePublished\":\"2025-10-30T15:01:16+00:00\",\"dateModified\":\"2025-10-30T15:01:17+00:00\",\"description\":\"ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK) announced a milestone license and collaboration agreement with Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) to develop multispecific antibodies across therapeutic areas of shared interest. The partnership will leverage ModeX\u2019s proprietary MSTAR (Multispecific Targeting for Antibody Recombinant) platform together with Regeneron\u2019s exclusive binding libraries, creating single\u2011molecule therapies that can target two or more distinct biological pathways simultaneously.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45335#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45335\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45335#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3006-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3006-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"ModeX Therapeutics Partners With Regeneron on Multispecific Antibody Platform\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45335#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ModeX Therapeutics Locks $1\u202fB+ Collaboration With Regeneron on Multispecific Antibody Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ModeX Therapeutics Locks $1\u202fB+ Collaboration With Regeneron on Multispecific Antibody Technology - Insight, China&#039;s Pharmaceutical Industry","description":"ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK) announced a milestone license and collaboration agreement with Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) to develop multispecific antibodies across therapeutic areas of shared interest. The partnership will leverage ModeX\u2019s proprietary MSTAR (Multispecific Targeting for Antibody Recombinant) platform together with Regeneron\u2019s exclusive binding libraries, creating single\u2011molecule therapies that can target two or more distinct biological pathways simultaneously.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45335","og_locale":"en_US","og_type":"article","og_title":"ModeX Therapeutics Locks $1\u202fB+ Collaboration With Regeneron on Multispecific Antibody Technology","og_description":"ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK) announced a milestone license and collaboration agreement with Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) to develop multispecific antibodies across therapeutic areas of shared interest. The partnership will leverage ModeX\u2019s proprietary MSTAR (Multispecific Targeting for Antibody Recombinant) platform together with Regeneron\u2019s exclusive binding libraries, creating single\u2011molecule therapies that can target two or more distinct biological pathways simultaneously.","og_url":"https:\/\/flcube.com\/?p=45335","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-30T15:01:16+00:00","article_modified_time":"2025-10-30T15:01:17+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3006-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45335#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45335"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"ModeX Therapeutics Locks $1\u202fB+ Collaboration With Regeneron on Multispecific Antibody Technology","datePublished":"2025-10-30T15:01:16+00:00","dateModified":"2025-10-30T15:01:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45335"},"wordCount":410,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45335#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3006-1.webp","keywords":["ModeX Therapeutics","Multi-specific antibodies","NASDAQ: OPK","NASDAQ: REGN","OPKO Health","Regeneron Pharmaceuticals"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45335#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45335","url":"https:\/\/flcube.com\/?p=45335","name":"ModeX Therapeutics Locks $1\u202fB+ Collaboration With Regeneron on Multispecific Antibody Technology - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45335#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45335#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3006-1.webp","datePublished":"2025-10-30T15:01:16+00:00","dateModified":"2025-10-30T15:01:17+00:00","description":"ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK) announced a milestone license and collaboration agreement with Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) to develop multispecific antibodies across therapeutic areas of shared interest. The partnership will leverage ModeX\u2019s proprietary MSTAR (Multispecific Targeting for Antibody Recombinant) platform together with Regeneron\u2019s exclusive binding libraries, creating single\u2011molecule therapies that can target two or more distinct biological pathways simultaneously.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45335#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45335"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45335#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3006-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3006-1.webp","width":1080,"height":608,"caption":"ModeX Therapeutics Partners With Regeneron on Multispecific Antibody Platform"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45335#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"ModeX Therapeutics Locks $1\u202fB+ Collaboration With Regeneron on Multispecific Antibody Technology"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3006-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45335","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45335"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45335\/revisions"}],"predecessor-version":[{"id":45341,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45335\/revisions\/45341"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45340"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45335"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45335"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45335"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}